Munich, Germany / Tokyo, Japan, June 15, 2023 — Adragos Pharma GmbH, a global leader in pharmaceutical manufacturing, announced today that it has completed the divestiture of its subsidiary Toride Pharma K.K., and its associated entity, Toride Asset Trading Co. […]

Adragos on a growth path: Three locations in Europe and five globally Acquisition strengthens Adragos’ end-to-end integrated pharmaceutical product development service offering Agreement on further product development activities for Clinigen Munich / London / Athens, April 3, 2023 – Munich-based […]

Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment Agreement includes further product development activities for Clinigen Limited Lamda spurs further growth for Adragos as its 3rd site […]

Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan Munich / Paris / Tokyo, March 02, 2023 – Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan’s […]

Adragos Pharma to acquire Sanofi’s manufacturing site in Kawagoe, Japan Munich / Paris / Tokyo, October 13, 2022 – Adragos Pharma, a rapidly growing pharmaceutical Contract Development and Manufacturing Organization (CDMO) based in Munich, Germany, signed definitive agreements with Sanofi […]

Munich / Plettenberg, 09. August 2021 – FSN Capital VI* (“FSNC”) has acquired a majority share in Adragos Pharma Group (“Adragos”), a growing B2B contract developer and manufacturer (CDMO) for pharmaceuticals. The current owner, Prange Group (“PG”), remains invested to […]